

# Tania Fleitas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3731422/publications.pdf>

Version: 2024-02-01

19  
papers

466  
citations

759233

12  
h-index

839539

18  
g-index

19  
all docs

19  
docs citations

19  
times ranked

882  
citing authors

#	ARTICLE	IF	CITATIONS
1	Personalized Medicine: Recent Progress in Cancer Therapy. <i>Cancers</i> , 2020, 12, 1009.	3.7	123
2	First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 877-885.	7.0	59
3	NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in <i>HER2</i> -Amplified Gastric Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 1639-1649.	7.0	47
4	Deregulation of <i>ARID1A</i> , <i>CDH1</i> , <i>cMET</i> and <i>PIK3CA</i> and target-related microRNA expression in gastric cancer. <i>Oncotarget</i> , 2015, 6, 26935-26945.	1.8	35
5	Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications. <i>ESMO Open</i> , 2019, 4, e000470.	4.5	35
6	Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer. <i>Cancers</i> , 2020, 12, 3611.	3.7	30
7	Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity. <i>Clinical Cancer Research</i> , 2017, 23, 5406-5415.	7.0	29
8	Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer. <i>ESMO Open</i> , 2020, 5, e000847.	4.5	21
9	Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. <i>British Journal of Cancer</i> , 2021, 125, 1261-1269.	6.4	14
10	MassARRAY determination of somatic oncogenic mutations in solid tumors: Moving forward to personalized medicine. <i>Cancer Treatment Reviews</i> , 2016, 49, 57-64.	7.7	13
11	A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. <i>ESMO Open</i> , 2019, 4, e000532.	4.5	13
12	Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. <i>Journal of Clinical Medicine</i> , 2020, 9, 3049.	2.4	12
13	Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment. <i>Oncotarget</i> , 2016, 7, 63424-63436.	1.8	12
14	Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology. <i>Oncotarget</i> , 2016, 7, 22543-22555.	1.8	11
15	A first-in-human trial of RG7116, a glycoengineered monoclonal antibody targeting HER3, in patients with advanced/metastatic tumors of epithelial cell origin expressing HER3 protein. <i>Journal of Clinical Oncology</i> , 2013, 31, 2522-2522.	1.6	5
16	In the literature: June 2019. <i>ESMO Open</i> , 2019, 4, e000547.	4.5	3
17	Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy. <i>Cancer Medicine</i> , 2019, 8, 3120-3130.	2.8	2
18	The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally. <i>BMC Cancer</i> , 2022, 22, .	2.6	2

#	ARTICLE	IF	CITATIONS
19	In the literature: December 2018. ESMO Open, 2018, 3, e000468.	4.5	0